Ascend Montclair Pharmacy Launches Medical CBD SalesNote

Aug.22.2022
Ascend Montclair Pharmacy Launches Medical CBD SalesNote
Ascend Montclair pharmacy launched medical CBD last weekend, drawing in a steady crowd of customers.

Last Saturday, Ascend Montclair pharmacy launched medical CBD products during their weekend sale, attracting a steady stream of customers to the pharmacy.

 

Michele DeZao, a 60-year-old from Rockaway, was also among those who came to inspect. Two months ago, she obtained a medical CBD card and this was her second time visiting the pharmacy.

 

The cancer-disabled patient in recovery immediately noticed that the crowd on Saturday was increasing. However, she was relieved to have received priority treatment in the queue reserved only for medical patients to be discharged.

 

The hours between 8am to 10am are reserved exclusively for medical patients, while adult tobacco purchases begin at 10am every day of the week at Ascend Montclair.

 

I have no problem," Dezo said while paying, claiming it helps alleviate stomach pain. "Anyway, people are buying it (adult tobacco), so why not make it legal?

 

On August 20, 2022, Michele DeZao picked up her medical marijuana from Ascend Montclair pharmacy. The pharmacy, located at 395 Bloomfield Avenue, officially opened its doors on Friday at 10am and became the 19th pharmacy in New Jersey to sell adult-use cannabis after weeks of negotiations with the town. Alexandra Pais of NJ Advance Media captured the moment.

 

We appreciate the support of the Montclair community and are excited to share the Ascend experience with people in Montclair and surrounding towns," said Caitlin Fleishman, Public Affairs and Communications Director for Ascend Wellness, the multi-state operator of the pharmacy.

 

Last Tuesday, the Montclair Township administration voted 5-1 in favor of a pre-negotiated settlement agreement with Ascend, allowing for the sale of adult tobacco products.

 

Peter Yacobellis, the town consultant, stated that as part of the settlement agreement, Ascend Montclair will provide "voluntary donations" to various organizations using revenue from adult tobacco sales.

 

In an email, Yacobellis praised Ascend for their incredible generosity towards the citizens of Montclair, particularly their contributions to the Montclair Community Development Corporation and the Montclair Pre-K program. Yacobellis also emphasized the importance of ensuring that low-income and communities of color benefit from the revenue generated by the new cannabis market, as these communities have been disproportionately impacted by legacy marijuana laws.

 

The owner and co-founder of Ascend announced that another New Jersey location in Roselle Park launched adult tobacco sales statewide on April 21 and quickly became one of their top-performing adult cannabis stores in the U.S.

 

Ascend Fort Lee began selling medical marijuana on August 12th and plans to expand into adult CBD in the fall.

 

At Ascend Montclair, "there is a lot of traffic and support," said Fleishman.

 

Statement:

 

This article is compiled from third-party information and is intended solely for industry professionals for discussion and study purposes.

 

This article does not represent the views of 2FIRSTS, nor can 2FIRSTS confirm the truthfulness or accuracy of the article's content. The translation of this article is only intended for industry exchange and research.

 

Due to limitations in translation ability, this article may not accurately reflect the meaning of the original text. Please refer to the original text for accuracy.

 

2FIRSTS is in full agreement with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan or international issues and positions.

 

The compilation information is the property of the original media and author. If there is any infringement, please contact us for deletion.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
The UK Insolvency Service said YSK Enterprises imported large quantities of vapes from China in 2023, with a shipment addressed to the company declared as medical nebulizers before Border Force found 352,688 vaping products. HMRC calculated nearly £15 million ($20.3 million) in unpaid VAT and customs duty, alongside about £437,000 in corporation tax. Two directors were disqualified for nine years. The case predates the UK's Vaping Products Duty, which will introduce vape-specific excise and duty-stamp requirements from October 2026.
Regulations
Sep.11
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
According to Free Malaysia Today on August 26, 2026, Malaysia’s Health Minister Dzulkefly Ahmad said the Health Ministry would explain the government’s decision to withdraw its appeal against a High Court ruling involving the exemption of liquid nicotine used in vape products from the Poisons List. The High Court previously ruled that the exemption decision was irrational. Dzulkefly said withdrawing the appeal did not mean the government would stop regulating vaping, and that future regulatory approaches would continue under existing legal frameworks.
Aug.28
2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
business accounting for 68.5% of sales. A new controlling investment in a Western European distributor and plans to scale modern oral nicotine pouches point to a broader international strategy spanning channels and multiple product categories.
Special Report
Aug.14
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives